论文部分内容阅读
目的探讨CAG与DA方案治疗老年急性髓系白血病的临床疗效。方法选取在平煤神马医疗集团总医院接受治疗的老年急性髓系白血病患者120例,随机分为CAG治疗组与DA治疗组,每组60例。CAG治疗组采用阿柔比星、小剂量阿糖胞苷以及粒细胞集落刺激因子进行治疗,DA治疗组采用柔红霉素和阿糖胞苷进行治疗。观察两组临床治疗效果。结果 CAG治疗组治疗有效率为75.00%;DA治疗组治疗有效率为71.67%。CAG治疗组与DA治疗组有效率经统计学检验,无显著差异(P<0.05)。CAG治疗组恶心、呕吐、腹泻、感染、出血、ALT异常、以及WBC1.0<10~9/L和PLT<2.020×10~9/L所占比例明显低于DA治疗组。经统计学检验,差异具有统计学意义(P<0.05)。结论 CAG与DA治疗老年急性髓系白血病临床疗效无显著差异,但CAG治疗方案不良反应少,值得推广。
Objective To investigate the clinical efficacy of CAG and DA regimen in the treatment of elderly patients with acute myeloid leukemia. Methods One hundred and twenty patients with acute myeloid leukemia treated at Pingmei Shenma Medical Group General Hospital were randomly divided into CAG treatment group and DA treatment group, 60 cases in each group. The CAG treatment group was treated with aclarubicin, low-dose cytarabine and granulocyte colony-stimulating factor, and the DA treatment group was treated with daunorubicin and cytarabine. Observe the clinical efficacy of the two groups. Results The effective rate was 75.00% in the CAG treatment group and 71.67% in the DA treatment group. The efficacy of CAG treatment group and DA treatment group was statistically tested and there was no significant difference (P<0.05). Nausea, vomiting, diarrhea, infection, hemorrhage, abnormal ALT, WBC 1.0<10~9/L and PLT<2.020*10~9/L were significantly lower in the CAG group than in the DA group. After statistical tests, the difference was statistically significant (P<0.05). Conclusion There is no significant difference in clinical efficacy between CAG and DA in the treatment of elderly patients with acute myeloid leukemia. However, CAG treatment has fewer adverse reactions and is worthy of promotion.